Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators

被引:385
作者
Bodenmiller, Bernd [1 ]
Zunder, Eli R. [1 ]
Finck, Rachel [1 ]
Chen, Tiffany J. [1 ,2 ,3 ]
Savig, Erica S. [1 ,4 ]
Bruggner, Robert V. [1 ,2 ]
Simonds, Erin F. [1 ]
Bendall, Sean C. [1 ]
Sachs, Karen [1 ]
Krutzik, Peter O. [1 ]
Nolan, Garry P. [1 ]
机构
[1] Stanford Univ, Dept Microbiol & Immunol, Baxter Lab Stem Cell Biol, Stanford, CA 94305 USA
[2] Stanford Univ, Biomed Informat Program, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA
[4] Stanford Univ, Canc Biol Program, Stanford, CA 94305 USA
基金
瑞士国家科学基金会;
关键词
KINASE INHIBITOR SELECTIVITY; POLYCHROMATIC FLOW-CYTOMETRY; FUNCTIONAL GENOMICS; DRUG DISCOVERY; IMMUNE-SYSTEM; CANCER; CELLS; PROTEOMICS; RESPONSES; POPULATIONS;
D O I
10.1038/nbt.2317
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Mass cytometry facilitates high-dimensional, quantitative analysis of the effects of bioactive molecules on human samples at single-cell resolution, but instruments process only one sample at a time. Here we describe mass-tag cellular barcoding (MCB), which increases mass cytometry throughput by using n metal ion tags to multiplex up to 2(n) samples. We used seven tags to multiplex an entire 96-well plate, and applied MCB to characterize human peripheral blood mononuclear cell (PBMC) signaling dynamics and cell-to-cell communication, signaling variability between PBMCs from eight human donors, and the effects of 27 inhibitors on this system. For each inhibitor, we measured 14 phosphorylation sites in 14 PBMC types at 96 conditions, resulting in 18,816 quantified phosphorylation levels from each multiplexed sample. This high-dimensional, systems-level inquiry allowed analysis across cell-type and signaling space, reclassified inhibitors and revealed off-target effects. High-content, high-throughput screening with MCB should be useful for drug discovery, preclinical testing and mechanistic investigation of human disease.
引用
收藏
页码:858 / U89
页数:12
相关论文
共 50 条
[11]   Phosphoproteomic Analysis Reveals Interconnected System-Wide Responses to Perturbations of Kinases and Phosphatases in Yeast [J].
Bodenmiller, Bernd ;
Wanka, Stefanie ;
Kraft, Claudine ;
Urban, Joerg ;
Campbell, David ;
Pedrioli, Patrick G. ;
Gerrits, Bertran ;
Picotti, Paola ;
Lam, Henry ;
Vitek, Olga ;
Brusniak, Mi-Youn ;
Roschitzki, Bernd ;
Zhang, Chao ;
Shokat, Kevan M. ;
Schlapbach, Ralph ;
Colman-Lerner, Alejandro ;
Nolan, Garry P. ;
Nesvizhskii, Alexey I. ;
Peter, Matthias ;
Loewith, Robbie ;
von Mering, Christian ;
Aebersold, Ruedi .
SCIENCE SIGNALING, 2010, 3 (153)
[12]   Interlinked fast and slow positive feedback loops drive reliable cell decisions [J].
Brandman, O ;
Ferrett, JE ;
Li, R ;
Meyer, T .
SCIENCE, 2005, 310 (5747) :496-498
[13]   Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry [J].
Chattopadhyay, Pratip K. ;
Price, David A. ;
Harper, Theresa F. ;
Betts, Michael R. ;
Yu, Joanne ;
Gostick, Emma ;
Perfetto, Stephen P. ;
Goepfert, Paul ;
Koup, Richard A. ;
De Rosa, Stephen C. ;
Bruchez, Marcel P. ;
Roederer, Mario .
NATURE MEDICINE, 2006, 12 (08) :972-977
[14]   Comprehensive analysis of kinase inhibitor selectivity [J].
Davis, Mindy I. ;
Hunt, Jeremy P. ;
Herrgard, Sanna ;
Ciceri, Pietro ;
Wodicka, Lisa M. ;
Pallares, Gabriel ;
Hocker, Michael ;
Treiber, Daniel K. ;
Zarrinkar, Patrick P. .
NATURE BIOTECHNOLOGY, 2011, 29 (11) :1046-U124
[15]   U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis [J].
Deisseroth, Albert ;
Kaminskas, Edvardas ;
Grillo, Joseph ;
Chen, Wei ;
Saber, Haleh ;
Lu, Hong L. ;
Rothmann, Mark D. ;
Brar, Satjit ;
Wang, Jian ;
Garnett, Christine ;
Bullock, Julie ;
Burke, Laurie B. ;
Rahman, Atiqur ;
Sridhara, Rajeshwari ;
Farrell, Ann ;
Pazdur, Richard .
CLINICAL CANCER RESEARCH, 2012, 18 (12) :3212-3217
[16]   Pharmacogenomics: Translating functional genomics into rational therapeutics [J].
Evans, WE ;
Relling, MV .
SCIENCE, 1999, 286 (5439) :487-491
[17]   A small molecule-kinase interaction map for clinical kinase inhibitors [J].
Fabian, MA ;
Biggs, WH ;
Treiber, DK ;
Atteridge, CE ;
Azimioara, MD ;
Benedetti, MG ;
Carter, TA ;
Ciceri, P ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Galvin, M ;
Gerlach, JL ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Insko, MA ;
Lai, AG ;
Lélias, JM ;
Mehta, SA ;
Milanov, ZV ;
Velasco, AM ;
Wodicka, LM ;
Patel, HK ;
Zarrinkar, PP ;
Lockhart, DJ .
NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336
[18]   Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses [J].
Geva-Zatorsky, Naama ;
Dekel, Erez ;
Cohen, Ariel A. ;
Danon, Tamar ;
Cohen, Lydia ;
Alon, Uri .
CELL, 2010, 140 (05) :643-651
[19]   Cell Sorting: Automated Separation of Mammalian Cells as a Function of Intracellular Fluorescence [J].
Hulett, H. R. ;
Bonner, W. A. ;
Barrett, Janet ;
Herzenberg, Leonard A. .
JOURNAL OF IMMUNOLOGY, 2014, 193 (05) :747-749
[20]   ERBB receptors and cancer: The complexity of targeted inhibitors [J].
Hynes, NE ;
Lane, HA .
NATURE REVIEWS CANCER, 2005, 5 (05) :341-354